A Dutch company is involved in preclinical R&D of therapeutic protein with a high potential in treatment of dermatological applications (e.g. psoriasis and burn-wounds diabetic ulcers). The technology has a large potential in the prevention or attenuation of progressive systemic pro-inflammatory responses . The company seeks collaboration or a joint venture with partners active in the biotech and pharma sector and/or investors.